Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Publication year range
1.
Hipertens. riesgo vasc ; 41(2): 118-131, abr.-jun2024. tab, ilus
Article in English | IBECS | ID: ibc-232397

ABSTRACT

Hypertensive disorders in pregnancy (HDP) remain a leading cause of pregnancy-related maternal and foetal morbidity and mortality worldwide, including chronic hypertension, gestational hypertension, and pre-eclampsia. Affected women and newborns also have an increased risk of cardiovascular disease later in life, independent of traditional cardiovascular disease risks. Despite these risks, recommendations for optimal diagnosis and treatment have changed little in recent decades, probably due to fear of the foetal repercussions of decreased blood pressure and possible drug toxicity. In this document we review the diagnostic criteria and classification of (HDP), as well as important aspects regarding pathophysiology and early detection that allows early identification of women at risk, with the aim of preventing both immediate and long-term consequences. Prophylactic treatment with aspirin is also reviewed early and a therapeutic approach is carried out that involves close maternal and foetal monitoring, and if necessary, the use of safe drugs in each situation. This review aims to provide an updated vision for the prevention, diagnosis, and treatment of HDP that is useful in our usual clinical practice.(AU)


Los estados hipertensivos del embarazo (EHE) siguen siendo una de las principales causas de morbilidad y mortalidad materna y fetal relacionada con el embarazo en todo el mundo, incluyen la hipertensión crónica, la hipertensión gestacional y la preeclampsia. Las mujeres afectadas y los recién nacidos también tienen un mayor riesgo de sufrir enfermedades cardiovasculares en el futuro, independientemente de los riesgos tradicionales de la enfermedad cardiovascular. A pesar de estos riesgos, las recomendaciones para un diagnóstico y un tratamiento óptimo han cambiado poco en las últimas décadas, probablemente por el miedo a las repercusiones fetales de la disminución de la presión arterial y la posible toxicidad farmacológica. En ese documento revisamos los criterios diagnósticos y la clasificación de los EHE, así como aspectos importantes en cuanto a fisiopatología y la detección temprana que permita la identificación precoz de las mujeres en riesgo, con el objetivo de prevenir tanto las secuelas inmediatas como a largo plazo. También se revisa el tratamiento profiláctico con aspirina de forma precoz y se realiza una aproximación terapéutica que implica una estrecha vigilancia materna y fetal, y si es necesario, el uso de fármacos seguros en cada situación. Esta revisión pretende dar una visión actualizada para la prevención, diagnóstico y tratamiento de los EHE que sea de utilidad en nuestra práctica clínica habitual.(AU)


Subject(s)
Humans , Female , Pregnancy , Pregnancy Complications , Pre-Eclampsia , Hypertension , Arterial Pressure , Morbidity , Hypertension, Pregnancy-Induced/mortality
2.
Hipertens Riesgo Vasc ; 41(2): 118-131, 2024.
Article in English | MEDLINE | ID: mdl-38508878

ABSTRACT

Hypertensive disorders in pregnancy (HDP) remain a leading cause of pregnancy-related maternal and foetal morbidity and mortality worldwide, including chronic hypertension, gestational hypertension, and pre-eclampsia. Affected women and newborns also have an increased risk of cardiovascular disease later in life, independent of traditional cardiovascular disease risks. Despite these risks, recommendations for optimal diagnosis and treatment have changed little in recent decades, probably due to fear of the foetal repercussions of decreased blood pressure and possible drug toxicity. In this document we review the diagnostic criteria and classification of (HDP), as well as important aspects regarding pathophysiology and early detection that allows early identification of women at risk, with the aim of preventing both immediate and long-term consequences. Prophylactic treatment with aspirin is also reviewed early and a therapeutic approach is carried out that involves close maternal and foetal monitoring, and if necessary, the use of safe drugs in each situation. This review aims to provide an updated vision for the prevention, diagnosis, and treatment of HDP that is useful in our usual clinical practice.


Subject(s)
Cardiovascular Diseases , Hypertension, Pregnancy-Induced , Pre-Eclampsia , Pregnancy , Infant, Newborn , Female , Humans , Hypertension, Pregnancy-Induced/diagnosis , Hypertension, Pregnancy-Induced/drug therapy , Pre-Eclampsia/diagnosis , Pre-Eclampsia/prevention & control , Risk Assessment
3.
Prog. obstet. ginecol. (Ed. impr.) ; 49(2): 98-101, feb. 2006. ilus
Article in Es | IBECS | ID: ibc-043011

ABSTRACT

Presentamos el caso de una paciente que acudió a urgencias por dolor holocraneal y pérdida de conocimiento. Había tenido a su cuarto hijo hacía 3 meses. Tras varios días de estudio, descubrimos fracción beta de la hormona gonadotropina coriónica humana (B HCG) en sangre elevada y metástasis sangrantes cerebrales, por lo que se diagnosticó metástasis de coriocarcinoma


We report the case of a patient who presented to the emergency department with holocranial pain and loss of consciousness. She had given birth to her fourth child 3 months previously. After several days of investigations, we observed a high serum beta-human chorionic gonadotrophin level and hemorrhagic brain metastases. These data led to a diagnosis of metastases from choriocarcinoma


Subject(s)
Female , Adult , Humans , Choriocarcinoma/pathology , Pregnancy Complications, Neoplastic/pathology , Uterine Neoplasms/pathology , Brain Neoplasms/secondary , Fatal Outcome
4.
Prog. obstet. ginecol. (Ed. impr.) ; 45(5): 218-221, mayo 2002. ilus
Article in Es | IBECS | ID: ibc-16463

ABSTRACT

La trombosis de la vena ovárica (TVO) es un trastorno poco frecuente. Presentamos un caso de TVO en paciente joven, asociado a tumoración ovárica benigna: teratoma de ovario derecho incarcerado en Douglas, que produce compresión del pedículo vascular y trombosis de la vena ovárica derecha. Aunque la TVO es infrecuente es importante tenerla en cuenta para evitar intervenciones quirúrgicas innecesarias y complicaciones graves secundarias (AU)


Subject(s)
Adult , Female , Humans , Thrombophlebitis/complications , Thrombophlebitis/diagnosis , Ovary/pathology , Ovary/injuries , Teratoma/complications , Teratoma/diagnosis , Clindamycin/administration & dosage , Clindamycin/therapeutic use , Gentamicins/administration & dosage , Gentamicins/therapeutic use , Anticoagulants/administration & dosage , Anticoagulants/therapeutic use , Ovarian Neoplasms/complications , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms , Hypogastric Plexus/pathology , Hypogastric Plexus , Ultrasonography, Doppler/methods
5.
Obstet Gynecol ; 96(3): 465-9, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10960643

ABSTRACT

OBJECTIVE: To compare efficacy, safety, and tolerance of oral misoprostol with intracervical dinoprostone for cervical ripening and labor induction. METHODS: Two hundred women were randomized to receive single doses of oral misoprostol 200 microg or 0.5 mg of dinoprostone intracervically every 6 hours for a maximum four doses. RESULTS: The intervals from administration of the drug to active phase of labor (11.1 hours [7-24] versus 15.8 hours [7.5-29.62], P =. 01), to delivery (14.0 hours [8.42-27.61] versus 20.2 hours [16.7-32. 8], P =.01), and to rupture of membranes (10.0 hours [4.95-24.7] versus 15.6 hours [8.2-29.2], P =.003) were significantly shorter in the misoprostol group. All those variables were not distributed normally, so results are presented as median and interquartile range. The rates of women who needed oxytocin (68% versus 52%, P =.03) and cesarean for failed induction (9% versus 1%, P =.01) were higher in the dinoprostone group. CONCLUSION: A single dose of 200 microg oral misoprostol was more effective for cervical ripening and labor induction than 0.5 mg of dinoprostone intracervically every 6 hours, with a maximum of four doses.


Subject(s)
Cervix Uteri/drug effects , Dinoprostone/administration & dosage , Labor, Induced , Misoprostol/administration & dosage , Oxytocics/administration & dosage , Administration, Intravaginal , Administration, Oral , Adult , Dinoprostone/adverse effects , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Humans , Infant, Newborn , Misoprostol/adverse effects , Oxytocics/adverse effects , Pregnancy , Treatment Outcome
6.
Eur J Obstet Gynecol Reprod Biol ; 82(2): 201-7, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10206416

ABSTRACT

OBJECTIVES: To measure maternal serum concentrations of total nitrites, as an index of nitric oxide synthesis, in normal and hypertensive pregnant women, and to examine the correlation between these concentrations and several variables of clinical interest. STUDY DESIGN: A total of 60 women in four different groups were studied: 10 normotensive pregnant women, 17 pregnant women with preeclampsia, 18 pregnant women with gestational hypertension and 15 pregnant women with chronic hypertension. Serum nitrite levels were determined using the Griess reaction after reduction with nitrate reductase. RESULTS: Serum nitrite levels were higher in preeclamptic women (34.11+/-14 micromol/l, P=0.04), lower in chronic hypertensive women (19.56+/-6.46 micromol/l, P=0.04) and similar in women with gestational hypertension (26.97+/-9.44 micromol/l) in comparison to the control group (25.37+/-7.24 micromol/l). Serum nitrite levels in preeclamptic women had significant positive correlations with hematocrit, fasting insulinemia, and apolipoprotein B and negative correlations with platelet count, serum phosphorus and glucose:insulin ratio. In pregnant women with chronic hypertension a negative correlation was found between serum nitrite levels and active partial thromboplastin time. In pregnant women with gestational hypertension, serum nitrite levels had negative correlations with birthweight and 24-h urine calcium, and positive correlations with mean corspuscular hemoglobin, 24-h urine sodium and maternal age. CONCLUSIONS: We suggest that in women with preeclampsia, a higher maternal nitric oxide level may act as a compensatory mechanism against hemoconcentration and platelet aggregation and that nitric oxide production may be related to some metabolic events. In women with gestational hypertension, higher serum nitrite levels may be related to clinical and biochemical findings common in preeclampsia. In chronic hypertension, a lower maternal nitric oxide level is related to the status of coagulation.


Subject(s)
Hypertension/blood , Nitric Oxide/blood , Pregnancy Complications, Cardiovascular/blood , Apolipoproteins B/blood , Birth Weight , Blood Glucose/metabolism , Calcium/urine , Erythrocyte Indices , Female , Gestational Age , Humans , Insulin/blood , Male , Partial Thromboplastin Time , Phosphorus/blood , Platelet Count , Pre-Eclampsia/blood , Pregnancy , Sodium/urine
SELECTION OF CITATIONS
SEARCH DETAIL
...